Pricing Log in Create free account
Saturday 17 October 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

112.95 0.32 −0.28%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
15.6×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Incyte Corporation 8-K filed Jun 9, 2026

Period ended Jun 8, 2026 · Filed · accepted 4:06 PM ET · Document on sec.gov · Filing index

5.07 Submission of matters to a vote of security holders